Core Viewpoint - The company faces increased uncertainty in its transformation journey due to the debt crisis of its controlling shareholder and changes in the board of directors [1][3]. Debt Crisis - The controlling shareholder, Zhejiang Xiaobei Damei Holdings Co., applied for pre-restructuring due to liquidity issues and inability to repay debts, which was approved by the court [3][4]. - As of July 23, Xiaobei Damei holds 132.6 million shares of the company, accounting for 12.28% of total shares, with 98.85% of these shares pledged or frozen [3][4]. - The company claims that the pre-restructuring will not significantly impact its daily operations, asserting its independence in business and financial matters [3][4]. Performance Fluctuations - The company's revenue peaked at over 6 billion yuan in 2013 but has since declined, with 2024 revenue reported at 2.773 billion yuan, less than half of its peak [5]. - The company has experienced five years of negative net profit over the past decade, with the highest loss exceeding 1 billion yuan in 2017 [5][6]. - Frequent performance revisions have led to the company being labeled as "A-share face-changing king," with multiple corrections to earnings forecasts and financial reports since 2013 [6]. Transformation Challenges - The company attempted to expand its product positioning to "full lifecycle health management" but faced challenges shortly after this announcement [7]. - The controlling shareholder has been listed as a dishonest executor, and there have been non-operational fund occupations amounting to 47.85 million yuan that were returned within the same year [7]. - The company has diversified into adult milk powder and high-end products, but new business segments account for less than 10% of total revenue as of 2024 [8]. - Factors contributing to the difficulties in transformation include resource dispersion, insufficient investment in core business, and frequent management changes leading to a lack of coherent operational strategies [8].